Related references
Note: Only part of the references are listed.Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma
Yuki Inada et al.
HEPATOLOGY (2019)
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Relationship of liver cancer with LRP1B or TP53 mutation and tumor mutation burden and survival.
Longrong Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma
Young K. Hong et al.
CELLULAR IMMUNOLOGY (2019)
Therapeutic advances for patients with intermediate hepatocellular carcinoma
Jin-Yu Sun et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
Xiufeng Liu et al.
ONCOLOGIST (2019)
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Weiqi Xu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
Maria-Luisa Schubert et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Safe Positioning for Sexual Intercourse After Proximal Femoral Replacement
Cory G. Couch et al.
ORTHOPEDICS (2018)
Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report
Fumiko Chino et al.
HEPATOLOGY (2018)
Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma
Mahnaz Seifi-Alan et al.
IMMUNOTHERAPY (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein
Zeyan Pan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
Carl DeSelm et al.
MOLECULAR THERAPY (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy
Florence K. Keane et al.
SEMINARS IN RADIATION ONCOLOGY (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling
X. Song et al.
ONCOGENE (2017)
CAR T-cell therapy of solid tumors
Carmen S. M. Yong et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Sanja Stevanovic et al.
SCIENCE (2017)
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Hua Li et al.
PROTEIN & CELL (2017)
Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions
Hwi Young Kim et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
Praveen Sridhar et al.
CANCERS (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
Longhao Sun et al.
TUMOR BIOLOGY (2016)
Population Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States
Oxana V. Makarova-Rusher et al.
CANCER (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area
K. Sideras et al.
BRITISH JOURNAL OF CANCER (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
Christina Dargel et al.
GASTROENTEROLOGY (2015)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Morten F. Gjerstorff et al.
ONCOTARGET (2015)
T cell receptor-therapy in HBV-related hepatocellularcarcinoma
Antonio Bertoletti et al.
ONCOIMMUNOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis
Fan Yang et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ
Ana Textor et al.
CANCER RESEARCH (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
Eishiro Mizukoshi et al.
HEPATOLOGY (2013)
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
Kunle Odunsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Expansion of interferon-gamma-producing multifunctional CD4+T-cells and dysfunctional CD8+T-cells by glypican-3 peptide library in hepatocellular carcinoma patients
Yanhui Xu et al.
CLINICAL IMMUNOLOGY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC
Tim F. Greten et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T Takayama et al.
LANCET (2000)
Share Paper
